Summit Therapeutics company profile

SMMT · NASDAQ · USD

Compare Summit Therapeutics
$10.67Change from previous close: −9.73%Absolute change: −$1.15

Close · November 17, 2026

Company profile

Summit Therapeutics has 265 employees and is headquartered in Miami, United States.

Its products are marketed in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of medicines. Its most advanced candidate, ivonescimab, is a bispecific antibody that combines PD-1 blockade with anti-angiogenesis activity, and it is being studied for non-small cell lung cancer and colorectal cancer. The company is also testing the antibody in combination with chemotherapy in phase III trials, including in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC and in first-line unresectable metastatic colorectal cancer.

Summit Therapeutics was founded in 2003 and is headquartered in Miami, Florida, where it employs 265 people. For the fiscal year ended 31 December 2025, the company reported a net loss of USD 1.1 billion, or about USD 1,079.6 million.

Company facts

Industry
Biotechnology
Headquarters
601 Brickell Key Drive, 33131, Miami
Employees
265
Chief executive
Robert W. Duggan
Founded
2003
Fiscal year
January - December
Listing
SMMT · NASDAQ
Currency
USD
ISIN
US86627T1088
Website
smmttx.com

Summit Therapeutics and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Summit TherapeuticsSMMTUnited States$11.32B2650.0%—
Bio-TechneTECHUnited States$11.43B3,00021.7%66.8
BioMarin PharmaceuticalBMRNUnited States$11.09B3,22116.3%146.8
Madrigal PharmaceuticalsMDGLUnited States$9.93B915-10.7%—
Corcept TherapeuticsCORTUnited States$9.36B7300.8%190.2
Halozyme TherapeuticsHALOUnited States$14.67B42356.8%38.3

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Summit Therapeutics with its competitors